American Association for Cancer Research

Skip to Main Content

Table 3.

NAT2 acetylator status in cancer patients (CRC⁺) and unaffected MMR gene mutation carriers (CRC⁻)

NAT2 phenotype	CRC⁺	CRC⁻
NAT2 phenotype		n (%)	n (%)
Slow acetylator	31 (26.5)	26 (27.7)
Fast acetylator	86 (73.5)	68 (72.3)
	P = 0.85

NAT2 phenotype	CRC⁺	CRC⁻
NAT2 phenotype		n (%)	n (%)
Slow acetylator	31 (26.5)	26 (27.7)
Fast acetylator	86 (73.5)	68 (72.3)
	P = 0.85